Merck agrees to $8.4 billion deal for antibiotics developer Cubist

Dec. 9, 2014

Healthcare giant Merck & Co., Inc. is to acquire antibiotics specialist Cubist Pharmaceuticals, Inc. for $8.4 billion, the company announced on Monday.

Healthcare giant Merck & Co., Inc. is to acquire antibiotics specialist Cubist Pharmaceuticals, Inc. for $8.4 billion, the company announced on Monday.

Merck has agreed to pay $102 per share in cash, representing a 35 percent premium to Cubist's average stock price for the last five trading days. The agreement also includes $1.1 billion in net debt and other considerations, taking the total transaction value to approximately $9.5 billion.

Cubist develops advanced antibiotics to treat serious and potentially life-threatening infections caused by a broad range of increasingly drug-resistant bacteria.

Combining its expertise with Merck's strong capabilities and global reach "will enable us to create a stronger position in hospital acute care while addressing critical areas of unmet medical need, such as antibiotic resistance," commented Kenneth C. Frazier, chairman and CEO of Merck.

The acquisition includes the antibiotic Cubicin, the only approved once-a-day therapy for both S. aureus bacteremia and complicated skin and skin structure infections (cSSSI).

Cubist also has an in-line and late-stage pipeline of anti-infective medicines. Among them is Zerbaxa, which is awaiting approval from the U.S. Food and Drug Administration.

Merck said last year that it would be focusing on the hospital acute care segment as one of its key priorities. The company expects this acquisition to enhance its hospital acute care business in a range of therapeutic areas, including Gram-positive and Gram-negative multi-drug resistant infections.

The addition of Cubist will add more than $1 billion of revenue in 2015. The transaction will be neutral to non-GAAP EPS in 2015 but is anticipated to be significantly accretive to non-GAAP EPS in 2016 and beyond.

The deal is expected to be completed in the first quarter of 2015.

Sponsored Recommendations

Choosing The Right Partner for CHIPS Act Investments

As the U.S. looks to invest in the semiconductor research and production using CHIPS Act 2022 funding, it's important to choose the right partner.

EMWD Uses Technology to Meet Sustainability Goals

Eastern Municipal Water District pilots artificial intelligence-enabled control and machine learning to help save energy, reduce costs, and improve quality.

Protein Processing Solutions: Automation & Control

For protein processors looking to address industry challenges, improve efficiency, and stay ahead in a competitive market, Rockwell Automation offers tailored automation, control...

Automotive Manufacturing Innovation: Smart Solutions for a Connected Future

Rockwell Automation provides automation and control systems tailored for the automotive and tire industries, supporting electric vehicle production, tire production, battery production...